Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02530255 · ClinicalTrials.gov registry record · NA
Telomerase Activator and Retinal Amyloid
A NA study of Alzheimer Disease, sponsored by Chippewa Valley Eye Clinic.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT02530255: Completed NA study of Alzheimer Disease, sponsored by Chippewa Valley Eye Clinic.
NCT02530255 is a NA study of Alzheimer Disease that has completed, run by Chippewa Valley Eye Clinic. The registered enrollment target is 48 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02530255, a NA study of Alzheimer Disease, has completed, sponsored by Chippewa Valley Eye Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and has a predictive value in Alzheimer's disease. Telomere attrition accounts for cellular aging and is felt to have a pivotal role in Alzheimer's disease. The investigators plan to screen individuals to select those having retinal amyloid then evaluate an oral telomerase activator to determine if its use can alter the RAI over time compared to placebo.
Primary Outcome
Measurement of amyloid fluorescence while taking cycloastragalone or placebo
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT cycloastragenol
- DIETARY_SUPPLEMENT placebo (for cycloastragenol)
Study Locations (1)
Wisconsin
- Chippewa Valley Eye Clinic - Eau Claire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-12-01 |
| Est. Completion | 2018-12-31 |
| Phase | NA |
What the finished NCT02530255 record still lists
NCT02530255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which cycloastragenol is the first listed.
NCT02530255 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02530255 about?
NCT02530255 is a clinical study titled "Telomerase Activator and Retinal Amyloid". A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and h...
What is the current status of trial NCT02530255?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2016-12-01. Estimated completion is 2018-12-31.
What conditions does trial NCT02530255 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT02530255?
The interventions under investigation include: cycloastragenol (DIETARY_SUPPLEMENT), placebo (for cycloastragenol) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02530255?
This trial is sponsored by Chippewa Valley Eye Clinic, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02530255 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02530255's enrollment target sits among peer trials
48 215th of 306 higher than 90 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI